. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Mayo Clin Proc. 2019 Jan 31;94(3):465–471. doi: 10.1016/j.mayocp.2018.08.041

Table 3.

Epidemiology Studies in AL amyloidosis

Reference	Location	Design	Age/ gender	Yearly incidence (per 100,000 person-years)
Current study	Olmsted county	1990–2015: Population-based study; primarily mass spectrometry typing	Median age: 76 years; males 54%	1.2 (95%CI 0.8, 1.6)^a
Duhamel⁹	Limosin region, France	2012 to 2016: Population-based study; no mention of amyloid typing methodology	Median age, 72.5 years; 70% men	1.25 (95% CI, 0.56−1.94)^b
Quock¹⁰	USA	2007 to 2015: US claims data	Mean age 64 years; 54% male	1.08 −1.52^a
Pinney⁶	England	2008: Extrapolated through death certificates and referral rates to and amyloidosis types at the NAC	Peaked at age 60–69;	0.3^c
Hemminki⁷	Sweden	2001 to 2018: Extrapolated through myeloma statistics and amyloid hospital discharge diagnoses	No data	0.32^c
Aguirre⁸	Argentina	2006 to 2015: Extrapolated through registrants in the Medical Care Program in Buenos Aires	No data	0.61 (95% CI, 0.26−0.97^a,d

NAC, National Amyloidosis Centre

Age and sex adjusted

Crude estimate

Adjusted for age only

Adjusted to the Buenos Aires Census (2010 census)